Status:
UNKNOWN
Cost-effectiveness of Controlling CPE
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Carbapenemase-producing Enterobacteriaceae Infections
Eligibility:
All Genders
18+ years
Brief Summary
Spread of extensively drug-resistant bacteria (XDR) such as carbapenemase-producing Enterobacterales (CPE) is a major public health problem. Various prevention and control interventions are implemente...
Detailed Description
Carbapenemase-producing Enterobacterales (CPE) are increasingly common in hospitals and represent a serious health problem. These multidrug-resistant organisms colonise the gastrointestinal tract afte...
Eligibility Criteria
Inclusion
- patients infected with emerging highly resistant bacteria at acute care hospital.
Exclusion
- patients infected while hospitalized in intensive care unit.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT05272410
Start Date
March 1 2022
End Date
September 1 2023
Last Update
March 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.